Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Receivables (2017 - 2021)

Historic Receivables for Protagonist Therapeutics (PTGX) over the last 5 years, with Q4 2021 value amounting to $1.6 million.

  • Protagonist Therapeutics' Receivables fell 3544.93% to $1.6 million in Q4 2021 from the same period last year, while for Dec 2021 it was $1.6 million, marking a year-over-year decrease of 3544.93%. This contributed to the annual value of $1.6 million for FY2021, which is 3544.93% down from last year.
  • Per Protagonist Therapeutics' latest filing, its Receivables stood at $1.6 million for Q4 2021, which was down 3544.93% from $2.6 million recorded in Q3 2021.
  • Protagonist Therapeutics' 5-year Receivables high stood at $7.1 million for Q2 2021, and its period low was $19000.0 during Q2 2017.
  • In the last 5 years, Protagonist Therapeutics' Receivables had a median value of $2.8 million in 2018 and averaged $3.1 million.
  • Its Receivables has fluctuated over the past 5 years, first surged by 3068421.05% in 2018, then tumbled by 6429.91% in 2019.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Receivables stood at $1.9 million in 2017, then skyrocketed by 52.29% to $2.9 million in 2018, then skyrocketed by 119.17% to $6.3 million in 2019, then plummeted by 61.22% to $2.4 million in 2020, then crashed by 35.45% to $1.6 million in 2021.
  • Its last three reported values are $1.6 million in Q4 2021, $2.6 million for Q3 2021, and $7.1 million during Q2 2021.